📰 Gregory Piazza News

Gregory Piazza News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Gregory Piazza. Real-time updates on events, politics, business and more.

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Anticoagulation | JAMA

February 16, 2024

This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),

Virginia Commonwealth University United States Comunidad Autonoma De Cataluna United Kingdom Columbia University New York

Source: jamanetwork.com

Thrombolex Announces Significant New Insights from the RESCUE Trial with the BASHIR™ Endovascular Catheter

October 24, 2023

Thrombolex, Inc., announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core...

United States Briang Firth Gregory Piazza Brian Firth Thrombolex Inc Harvard Medical School

Source: pr.com

No Benefit of Rivaroxaban in COVID Outpatients: PREVENT-HD

November 10, 2022

PREVENT-HD is the largest randomized study to look at anticoagulation in nonhospitalized COVID-19 patients and joins a long list of smaller trials also showing no benefit with this approach.

United States Renato Lopes Gregory Piazza American Heart Association Duke University Medical Center International Society On Thrombosis

Source: medscape.com

EHR-based Thromboembolism Risk Tools Boosts Prophylaxis

November 9, 2022

A clinical decision-support tool designed to identify hospitalized patients in need of VTE prophylaxis cut the rate of thromboembolism at 30 days in the randomized IMPROVE-DD VTE trial.

United States New York Boston University Alexc Spyropoulos Elainem Hylek Gregory Piazza

Source: medscape.com

Anticoagulation Again Flops for Outpatient COVID-19

November 8, 2022

Largest-yet RCT shows no benefit for non-hospitalized symptomatic patients despite elevated risk

United States North Carolina Gregory Piazza American Heart Association Duke Clinical Research Institute In Durham Harvard Medical School

Source: medpagetoday.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation